| Year |
Citation |
Score |
| 2020 |
Rossi F, Josey B, Sayitoglu EC, Potens R, Sultu T, Duru AD, Beljanski V. Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells. Plos One. 15: e0239238. PMID 32941515 DOI: 10.1371/Journal.Pone.0239238 |
0.314 |
|
| 2019 |
Rossi F, Noren H, Sarria L, Schiller PC, Nathanson L, Beljanski V. Combination therapies enhance immunoregulatory properties of MIAMI cells. Stem Cell Research & Therapy. 10: 395. PMID 31852519 DOI: 10.1186/S13287-019-1515-3 |
0.308 |
|
| 2019 |
Beljanski V, Grinnemo KH, Österholm C. Pleiotropic roles of autophagy in stem cell-based therapies. Cytotherapy. PMID 30876741 DOI: 10.1016/J.Jcyt.2019.02.007 |
0.353 |
|
| 2017 |
Olagnier D, Lababidi RR, Hadj SB, Sze A, Liu Y, Naidu SD, Ferrari M, Jiang Y, Chiang C, Beljanski V, Goulet ML, Knatko EV, Dinkova-Kostova AT, Hiscott J, Lin R. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28527723 DOI: 10.1016/J.Ymthe.2017.04.022 |
0.356 |
|
| 2015 |
Beljanski V, Chiang C, Hiscott J. The intersection between viral oncolysis, drug resistance, and autophagy. Biological Chemistry. 396: 1269-80. PMID 26068902 DOI: 10.1515/Hsz-2015-0147 |
0.383 |
|
| 2015 |
Chiang C, Beljanski V, Yin K, Olagnier D, Ben Yebdri F, Steel C, Goulet ML, DeFilippis VR, Streblow DN, Haddad EK, Trautmann L, Ross T, Lin R, Hiscott J. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists. Journal of Virology. 89: 8011-25. PMID 26018150 DOI: 10.1128/Jvi.00845-15 |
0.326 |
|
| 2015 |
Hiscott J, Chiang C, Beljanski V. ID: 258 Cytokine. 76: 111. DOI: 10.1016/J.Cyto.2015.08.254 |
0.317 |
|
| 2014 |
Olagnier D, Peri S, Steel C, van Montfoort N, Chiang C, Beljanski V, Slifker M, He Z, Nichols CN, Lin R, Balachandran S, Hiscott J. Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. Plos Pathogens. 10: e1004566. PMID 25521078 DOI: 10.1371/Journal.Ppat.1004566 |
0.326 |
|
| 2014 |
Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, Nguyên TL, Di Lenardo T, Semmes OJ, Lin R, Hiscott J. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. Journal of Virology. 88: 2927-40. PMID 24371063 DOI: 10.1128/Jvi.03406-13 |
0.363 |
|
| 2013 |
Samuel S, Beljanski V, Van Grevenynghe J, Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C, Goulet ML, Shamy A, Brown D, Abesada G, Haddad EK, Hiscott J. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1413-23. PMID 23689597 DOI: 10.1038/Mt.2013.91 |
0.355 |
|
| 2012 |
Beljanski V, Hiscott J. The use of oncolytic viruses to overcome lung cancer drug resistance. Current Opinion in Virology. 2: 629-35. PMID 22910124 DOI: 10.1016/J.Coviro.2012.07.006 |
0.313 |
|
| 2011 |
Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biology & Therapy. 11: 524-34. PMID 21258214 DOI: 10.4161/Cbt.11.5.14677 |
0.307 |
|
| 2011 |
Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Investigational New Drugs. 29: 1132-42. PMID 20473784 DOI: 10.1007/S10637-010-9452-0 |
0.341 |
|
| 2010 |
Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. The Journal of Pharmacology and Experimental Therapeutics. 333: 454-64. PMID 20179157 DOI: 10.1124/Jpet.109.163337 |
0.367 |
|
| 2010 |
French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. The Journal of Pharmacology and Experimental Therapeutics. 333: 129-39. PMID 20061445 DOI: 10.1124/Jpet.109.163444 |
0.361 |
|
| 2009 |
Beljanski V, Knaak C, Zhuang Y, Smith C. Abstract B251: Combined anticancer effects of sphingosine kinase inhibitors and sorafenib Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B251 |
0.353 |
|
| 2007 |
Mack JT, Townsend DM, Beljanski V, Tew KD. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Current Drug Metabolism. 8: 47-57. PMID 17266523 DOI: 10.2174/138920007779315044 |
0.31 |
|
| 2006 |
Mack JT, Beljanski V, Tew KD, Townsend DM. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 60: 587-92. PMID 17029687 DOI: 10.1016/J.Biopha.2006.07.090 |
0.302 |
|
| 2005 |
Beljanski V, Villanueva JM, Doetsch PW, Natile G, Marzilli LG. Marked dependence on carrier-ligand bulk but not on carrier-ligand chirality of the duplex versus single-strand forms of a DNA oligonucleotide with a series of G-Pt(II)-G intrastrand cross-links modeling cisplatin-DNA adducts. Journal of the American Chemical Society. 127: 15833-42. PMID 16277526 DOI: 10.1021/Ja053089N |
0.388 |
|
| 2004 |
Beljanski V, Marzilli LG, Doetsch PW. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Molecular Pharmacology. 65: 1496-506. PMID 15155842 DOI: 10.1124/Mol.65.6.1496 |
0.434 |
|
| Show low-probability matches. |